Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
- PMID: 32471301
- PMCID: PMC7312459
- DOI: 10.3390/ijms21113816
Exercise Oncology and Immuno-Oncology; A (Future) Dynamic Duo
Abstract
Recent advances in clinical oncology is based on exploiting the capacity of the immune system to combat cancer: immuno-oncology. Thus, immunotherapy of cancer is now used to treat a variety of malignant diseases. A striking feature is that even patients with late-stage disease may experience curative responses. However, most patients still succumb to disease, and do not benefit from treatment. Exercise has gained attention in clinical oncology and has been used for many years to improve quality of life, as well as to counteract chemotherapy-related complications. However, more recently, exercise has garnered interest, largely due to data from animal studies suggesting a striking therapeutic effect in preclinical cancer models; an effect largely mediated by the immune system. In humans, physical activity is associated with a lower risk for a variety of malignancies, and some data suggest a positive clinical effect for cancer patients. Exercise leads to mobilization of cells of the immune system, resulting in redistribution to different body compartments, and in preclinical models, exercise has been shown to lead to immunological changes in the tumor microenvironment. This suggests that exercise and immunotherapy could have a synergistic effect if combined.
Keywords: cancer; exercise; immune system; immunotherapy; physical activity.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures

Similar articles
-
Immuno-oncology-101: overview of major concepts and translational perspectives.Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11. doi: 10.1016/j.semcancer.2018.02.005. Epub 2018 Feb 8. Semin Cancer Biol. 2018. PMID: 29428479 Review.
-
Exercise as Adjunct Therapy in Cancer.Semin Radiat Oncol. 2019 Jan;29(1):16-24. doi: 10.1016/j.semradonc.2018.10.001. Semin Radiat Oncol. 2019. PMID: 30573180 Free PMC article. Review.
-
Integrative Pharmacology: Advancing Development of Effective Immunotherapies.AAPS J. 2018 Apr 27;20(4):66. doi: 10.1208/s12248-018-0229-2. AAPS J. 2018. PMID: 29704129 Review.
-
Run for your life: an integrated virtual tissue platform for incorporating exercise oncology into immunotherapy.Cancer Immunol Immunother. 2021 Jul;70(7):1951-1964. doi: 10.1007/s00262-020-02790-7. Epub 2021 Jan 8. Cancer Immunol Immunother. 2021. PMID: 33416943 Free PMC article.
-
Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures.J Vasc Interv Radiol. 2017 Nov;28(11):1487-1494. doi: 10.1016/j.jvir.2017.07.018. Epub 2017 Sep 12. J Vasc Interv Radiol. 2017. PMID: 28912090 Review.
Cited by
-
The Significance of Longitudinal Psoas Muscle Loss in Predicting the Maintenance Efficacy of Durvalumab Treatment Following Concurrent Chemoradiotherapy in Patients with Non-Small Cell Lung Cancer: A Retrospective Study.Cancers (Basel). 2024 Aug 30;16(17):3037. doi: 10.3390/cancers16173037. Cancers (Basel). 2024. PMID: 39272894 Free PMC article.
-
Effects of exercise on immune cells with tumor-specific activity in breast cancer patients and survivors: a systematic review and meta-analysis.Support Care Cancer. 2023 Aug 5;31(9):507. doi: 10.1007/s00520-023-07968-0. Support Care Cancer. 2023. PMID: 37542543
-
Immunomodulatory effects of exercise in cancer prevention and adjuvant therapy: a narrative review.Front Physiol. 2024 Jan 4;14:1292580. doi: 10.3389/fphys.2023.1292580. eCollection 2023. Front Physiol. 2024. PMID: 38239881 Free PMC article. Review.
-
Restoring Epigenetic Reprogramming with Diet and Exercise to Improve Health-Related Metabolic Diseases.Biomolecules. 2023 Feb 7;13(2):318. doi: 10.3390/biom13020318. Biomolecules. 2023. PMID: 36830687 Free PMC article. Review.
-
Logical Intelligence and Mathematical Competence Are Determined by Physical Fitness in a Sample of School Children.Front Psychol. 2022 May 12;13:833844. doi: 10.3389/fpsyg.2022.833844. eCollection 2022. Front Psychol. 2022. PMID: 35645885 Free PMC article.
References
-
- Reck M., Schenker M., Lee K.H., Provencio M., Nishio M., Lesniewski-Kmak K., Sangha R., Ahmed S., Raimbourg J., Feeney K., et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non–small-cell lung cancer with high tumour mutational burden: Patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial. Eur. J. Cancer. 2019;116:137–147. doi: 10.1016/j.ejca.2019.05.008. - DOI - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical